Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TGTX
HoldPremium GrowerFLAGTG Therapeutics, Inc. · Healthcare · United States · $8.3B · Avg Vol: $120M/d
TG Therapeutics has exceptional momentum at M84 with a buyback and a 4.8% upward revision, but value at V25 is below the calibrated floor and quality Q66 is offset, so stage one fails.
COMPANY DESCRIPTION
TG Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell mediated diseases, particularly multiple sclerosis and B-cell lymphomas. The company operates in a highly specialized pharmaceutical niche, with its competitive edge reliant on the efficacy and approval of its proprietary drug candidates like ublituximab (Briumvi). As a clinical-stage company with an approved product, it addresses areas of high unmet medical need.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.8M | 233.7M | 329.0M | 616.3M | 504.9% | 799.5M | 960.2M | 1.3B | 46.2% |
| EPS | -1.46 | 0.09 | 0.16 | 3.10 | 486.9% | 2.74 | 1.76 | 3.67 | 8.8% |
| Shares | 146.4M | 151.4M | 155.8M | 155.3M | +6.1% | 153.1M | — | — | — |
| Debt | 83.1M | 110.8M | 253.7M | 253.7M | 45.1% | 754.4M | — | — | — |
| Equity | 58.6M | 160.5M | 222.4M | 648.0M | 122.8% | — | — | — | — |
| Op CF | -176.2M | -31.4M | -40.5M | -24.8M | — | 17.9M | — | — | — |
| Inv CF | -20.0M | -50.7M | -1.0M | 13.8M | — | — | — | — | — |
| Fin CF | -0.4M | 72.7M | 128.5M | -89.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TGTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TGTX | TG Therapeutics, Inc.(you) | $8.3B | 57 | Hold |
| CAI | Caris Life Sciences, Inc. | $7.2B | 60 | Hold |
| TVTX | Travere Therapeutics, Inc. | $6.2B | 54 | Hold |
| BMRN | BioMarin Pharmaceutical Inc. | $12.5B | 63 | Hold |
| PTGX | Protagonist Therapeutics, Inc. | $9.3B | 44 | Hold |
| LGND | Ligand Pharmaceuticals Incorporated | $5.6B | 67 | Buy |
| BLTE | Belite Bio, Inc | $6.1B | 42 | Hold |
| KRYS | Krystal Biotech, Inc. | $10.4B | 74 | Buy |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 71 | Buy |
| TECH | Bio-Techne Corporation | $11.3B | 76 | Buy |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.1%